Penetration of the Innovative Antibiotic Gepotidacin Into Prostate &

Status Completed

Clinical Trial Summary

Gepotidacin is a new antibiotic that may potentially be used to treat prostatic infections and pharyngeal gonorrhoea. To date, no data exists on gepotidacin pharmacokinetics in those tissues. The present study is being carried out to determine concentrations of gepotidacin in plasma, prostate and tonsillar tissue of patients undergoing radical prostatectomy (RPE) for localized prostate, simple prostatectomy (PE) for benign prostate hyperplasia (BPH) or tonsillectomy (TE). This will contribute to a more complete understanding of the drug's penetration to its site of action.

Clinical Trial Description

A single dose of 1500 mg gepotidacin will be administered to patients who will undergo radical prostatectomy (RPE) or simple prostatectomy (PE) and patients undergoing tonsillectomy (TE). The individual time-points of gepotidacin administration will be chosen to ensure that the time-point of tissue removal corresponds with one of six different sampling time-points, as closely as possible. After study drug administration RPE or TE will be performed according to clinical routine. Subsequently, microdialysis (MD) probes will be inserted in the removed tissue (tonsillar or prostate tissue) ex-vivo and MD will be performed to determine unbound drug concentrations in the tissue. Plasma PK samples will be collected just before study drug administration and up to 48h after administration of gepotidacin. Since MD provides the concentration of the unbound fraction of gepotidacin, for comparison we will calculate the unbound fraction of the concentration values obtained through blood sampling. To this end, we will determine the protein binding using ultrafiltration for each subject at the time-point closest to the Cmax. The individual protein binding can then be used to calculate the unbound plasma fraction of gepotidacin. This will allow to transform the plasma PK data to the same scale as the microdialysis data. Samples will be analysed using non-compartmental analysis (NCA) for plasma concentrations and population pharmacokinetic models (PopPK) for tissue concentrations pooled with plasma concentrations. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04484740
Study type	Interventional
Source	Institut National de la Santé Et de la Recherche Médicale, France
Contact
Status	Completed
Phase	Phase 1
Start date	January 29, 2021
Completion date	May 27, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05846399` - CAT BITE Antibiotic Prophylaxis for the Hand/Forearm (CATBITE)	Phase 4
Recruiting	`NCT05904535` - Novel Diagnostic Methods to Identify External Ventricular Drain Associated Infections
Not yet recruiting	`NCT04075344` - Effect of a Infection Control Program on the Reduction of Bacterial Contamination on NG Tube Feeding in RCHEs	N/A
Completed	`NCT05333133` - High Calorie Formula Intervention on Weight, Length Increment, Total Lymphocyte Counts, TNF-alpha and IGF-1 in Failure to Thrive Children	N/A
Recruiting	`NCT05950984` - Medical Device (MD) Derived Pharmacokinetic (PK) Parameters for Vancomycin (MD-PK)
Recruiting	`NCT06283433` - A Dried Blood Spot Sampling Method for Vancomycin and Creatinine Monitoring for OPAT	N/A
Recruiting	`NCT06178822` - Towards Novel BIOmarkers to Diagnose SEPsis on the Emergency Room
Completed	`NCT03688321` - Probiotic on Prevention of GBS Vaginal Infection During Pregnancy	N/A
Completed	`NCT03244917` - Trial to Reduce Antimicrobial Use In Nursing Home Residents With Alzheimer's Disease and Other Dementias	N/A
Recruiting	`NCT04450680` - Beta-lactam Therapeutic Drug Monitoring in Singapore
Completed	`NCT05686577` - How to Reduce Unnecessary Blood Cultures: Construction and Validation of a Predictive Score for Blood Culture Positivity in Intensive Care
Recruiting	`NCT06093269` - Pharmacokinetics Study of Cefazolin in Hemodialysis (CEFAZODIAL)	Phase 4
Recruiting	`NCT05587283` - Safety, Tolerability, and Acceptability Study of Intravaginal Administration of LABTHERA-001 Capsules in Healthy Women	Phase 1
Recruiting	`NCT03752424` - Topical Silver Nanoparticles for Microbial Activity	Phase 1
Completed	`NCT04440631` - Gut Microbiome of Patients Undergoing Antibiotic Therapy for Orthopedic Device-related Infection
Active, not recruiting	`NCT05150015` - ElastoMeric Infusion Pumps for Hospital AntibioTICs	N/A
Completed	`NCT03816956` - Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301	Phase 3
Terminated	`NCT03555981` - Early Kangaroo Mother Care in Gambian Hospitalised Unstable Neonates	N/A
Completed	`NCT03133312` - Chlorhexidine Gluconate Versus Povidone-Iodine as Vaginal Preparation Antiseptics Prior to Cesarean Delivery	Phase 4
Recruiting	`NCT04800575` - Comparison of Sterile Gauze and Semi-permeable Film Dressing for Hemodialysis Central Venous Catheter	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Penetration of the Innovative Antibiotic Gepotidacin Into Prostate and Tonsillar Tissue — AB-Direct

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms